The global kidney fibrosis treatment market is expected to register growth over the forecast period, driven by an increasing prevalence of chronic diseases such as the kidney. Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively. Changing lifestyle coupled with changing food habits is the prime reason for the rising base of kidney disease patients and is expected to boost the market for kidney fibrosis treatment. Furthermore, factors such as increasing the global geriatric population base, rising disposable income of the patients, and growing awareness about renal fibrosis treatment are vital factors for the growth of this market during the forecast period. Continuous innovation in technology has led to the development of safe and effective therapies for the treatment of chronic kidney diseases is also pushing the growth of kidney fibrosis treatment market. The introduction of promising drugs in the market coupled with favorable government initiative is expected to fuel the growth of this market owing to the increasing survival rate and effectiveness of these medicines in renal patients. The emerging nations such as India and China possess significant growth opportunities for kidney fibrosis treatment market owing to increasing medical expenditure and rising medical tourism rate.
The global kidney fibrosis treatment market is segmented on the basis of therapeutics and end use. On the basis of therapeutics, the market is further classified into angiotensin-converting enzyme (ACE) inhibitors, pirfenidone, renin inhibitors, angiotensin II receptor blockers (ARBs) and vasopeptidase inhibitors. Angiotensin-converting enzyme inhibitors is expected to witness lucrative growth over the forecast period owing to its ability to control the blood pressure by regulating the volume of fluid present in the blood. By end-use, the global kidney fibrosis treatment market is again divided into clinic-, hospital-, and home-based treatments. Hospital held the largest market share in 2014, in terms of revenue. Owing to increasing personal disposable income and rising awareness about hospital-based kidney treatment this segment is expected to continue its dominance over the forecast period.
North America was the dominant market in kidney fibrosis treatment in 2014 in terms of market share. Due to the large population base of people suffering from chronic kidney diseases, this region is anticipated to show a significant growth rate over the forecast period. Initiation of treatment for end-stage kidney treatment in the U.S. since 2011 is a vital growth propeller for this market. Asia Pacific region is anticipated to be the fastest-growing segment over the forecast period owing to increasing medical expenditure, a rise in disposable income, growing CRO activities and rising medical treatment.
The kidney fibrosis treatment market is highly consolidated and competitive in nature. The firms are involved in mergers, acquisition, geographical expansion, and strategic collaboration to survive and excel in the long run. The firms also plan to invest funds as sunk cost for continuous improvement. Key market players of the global kidney fibrosis treatment market are Merck & Co., Pfizer Inc., F. Hoffman-La Roche Ltd., InterMune Inc., Galectin Therapeutics, La Jolla Pharmaceutical Company, ProMetic Life-Sciences Inc., BioLine Rx Ltd., and Genzyme Corporation.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.